Omeros Corp (OMER) Gets a Buy Rating from Maxim Group

By Jason Carr

Maxim Group analyst Jason McCarthy maintained a Buy rating on Omeros Corp (NASDAQ: OMER) today and set a price target of $32. The company’s shares opened today at $24.54, close to its 52-week high of $27.

McCarthy commented:

“As expected, the pass-through status for Part B was re-instated. The extension of pass-through status will remain in effect until 10/1/2020. The next step is to secure permanent separate payment, which Omeros is working towards.”

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 20.9% and a 56.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omeros Corp with a $29 average price target.

See today’s analyst top recommended stocks >>

Based on Omeros Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.7 million. In comparison, last year the company had a GAAP net loss of $7.48 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.